The global doxycycline hyclate injection market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Doxycycline hyclate injection is used to treat or prevent bacterial infections, including pneumonia and other respiratory tract infections. The global doxycycline hyclate injection market is growing due to the rising prevalence of pneumonia globally. According to the World Health Organization (WHO) in November, pneumonia accounts for 14% of all deaths of children of age less than 5 years, accounting for 740,180 children in 2019.
Click Here to Get a Free Sample Report of the Doxycycline Hyclate Injection Market @ https://orionmarketreports.com/request-sample/?id=104629&submit=Request+Sample%0D%0A
The rising prevalence of bacterial infection and respiratory tract infection globally is also driving the demand for the doxycycline hyclate injection market. According to the WHO, respiratory tract infection accounts for more than 4 million fatalities annually. Additionally, in several countries, healthcare professionals prescribed doxycycline hyclate injection with other medicines to treat COVID-19 patients which has also boosted the demand for doxycycline hyclate injection globally. The development in healthcare infrastructure and the adoption of new treatments is also driving the growth of the market. Furthermore, various government and non-government initiatives to bring awareness about these diseases and their treatments are also boosting the growth of the global doxycycline hyclate injection market.
Get Discount on Buying this Report: https://orionmarketreports.com/request-discount/?id=104629&submit=Request+Discount
The market players are also contributing significantly to the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships, collaborations, and new drug launches, to stay competitive in the market. For instance, in July 2020, Zydus Group received the USFDA approval for manufacturing doxycycline injections at its Jarod facility, in Gujarat, India to treat bacterial infections, including pneumonia and other respiratory tract infections. Similarly, in June 2021, Hikma Pharmaceuticals PLC announced the launch of doxycycline for injection, USP, 100mg, in the US market.
A full report of Global Doxycycline Hyclate Injection Market is available at: https://orionmarketreports.com/doxycycline-hyclate-injection-market/104629/
Market Coverage
- The market number available for – 2022-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
- By Application
- Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Competitive Landscape- Mylan N.V., Zydus Group, Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Pfizer Inc., and Cipla Inc., among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
- Deviation from the pre-COVID-19 forecast
- Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Doxycycline Hyclate Injection Market Report by Segment
By Application
- Hospital
- Clinics
- Recovery Center
About Us:
Orion Market Reports (OMR) endeavors to provide an exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and the most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.
Media Contact:
Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404
